Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference

by B2i | Jan 6, 2025 | Press Releases

JUPITER, Fla., Jan. 06, 2025 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...

Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology

by B2i | Nov 21, 2024 | Press Releases

Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable TherapeuticsJUPITER, Fla., Nov. 21, 2024 — Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced today that it has been awarded a $3...

Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets

by B2i | Nov 12, 2024 | Press Releases

Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Alternative Proteins Demonstrated substantial revenue increase for Q3 2024, driven primarily by Dapibus™ license...

Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

by B2i | Nov 4, 2024 | Press Releases

JUPITER, Fla., Nov. 04, 2024 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...

Dyadic Expands Global Presence with Participation in Key Industry Events

by B2i | Oct 9, 2024 | Press Releases

JUPITER, Fla., Oct. 09, 2024 — Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the large-scale, efficient manufacturing of proteins for human and animal vaccines, therapeutics, and...

Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference

by B2i | Sep 23, 2024 | Press Releases

JUPITER, Fla., Sept. 23, 2024 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient, large-scale manufacture of...